Aldeyra’s dry eye drug suffers second FDA rejection, but imminent data spur hope of fast recovery
The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for its dry eye disease treatment, rejecting its second application for approval and calling for data from at least one more study. But with a trial set to read out this quarter, the biotech is aiming to bounce back and resubmit its application post-haste.
The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for its dry eye disease treatment, rejecting its second application for approval and calling for data from at least one more study. But with a trial set to read out this quarter, the biotech is aiming to bounce back and resubmit its application post-haste.
